Abstract:The author requested to add a co-author after the publication of the original article [1]. In this correction, the author has been added in the article entitled "GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma" in the journal "Current Drug Targets" 2021; 22(13), 1485-1495. Details of the error and a correction are provided here. The original editorial can be found online at 10.2174/1389450122666210204203950 We regret any errors and apologize to the readers. Original: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea Corrected: Sitansu S. Nanda1, Md Imran Hossain1, Heongkyu Ju2, Georgia C. Papaefthymiou3 and Dong Kee Yi1,* 1Department of Chemistry, Myongji University, Yongin, 03674, South Korea; 2Department of Physics, Gachon University, Seongnam-si, Gyeonggi-do, South Korea 3Department of Physics, Villanova University, Villanova, Pennsylvania19085, USA.

Correction: Curcio et al. The Histone Deacetylase Family: Structural Features and Application of Combined Computational Methods. Pharmaceuticals 2024, 17, 620

Erratum: Histone H3 lysine 4 monomethylation modulates long-range chromatin interactions at enhancers

Corrigendum for “A Novel Kinase Subverts Aluminium Resistance by Boosting Ornithine Decarboxylase‐dependent Putrescine Biosynthesis”

Correction to "Novel Antiproliferative Chimeric Compounds with Marked Histone Deacetylase Inhibitory Activity"

Correction: Supramolecularly Engineered Phospholipids Constructed by Nucleobase Molecular Recognition: Upgraded Generation of Phospholipids for Drug Delivery

Correction: Corrigendum: Autophagy-associated alpha-arrestin signaling is required for conidiogenous cell development in Magnaporthe oryzae

Author Correction: Structural insights into the activation of metabotropic glutamate receptors

Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27, 8282

Correction to "A Multiscale Study of Phosphorylcholine Driven Cellular Phenotypic Targeting"

Erratum: (4R)-Ethyl 4-(4-chloro-phen-yl)-2-hydr-oxy-5-oxo-2,3,4,5-tetra-hydro-pyrano[3,2-c]chromene-2-carboxyl-ate. Corrigendum.

Correction to “discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3”

Correction to "The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy"

Correction to “Structural Landscape of α-Acetamidocinnamic Acid Cocrystals with Bipyridine-Based Coformers: Influence of Crystal Packing on Their Thermal and Photophysical Properties”

Correction: The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions

Author Correction: Histone deacetylase function in CD4+ T cells

Correction to 'The levels of p53 govern the hierarchy of DNA damage tolerance pathway usage'

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Correction: Cui, H., et al. BA-12 Inhibits Angiogenesis via Glutathione Metabolism Activation. Int. J. Mol. Sci. 2019, 20, 4062

Corrigendum: Nα -acetyl-L-ornithine deacetylase from Escherichia coli and a ninhydrin-based assay to enable inhibitor identification

Correction: Al Khatib et al. Inhaled Medicines for Targeting Non-Small Cell Lung Cancer. Pharmaceutics 2024, 15, 2777

Corrigendum to: GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma